Successful Treatment of Chronic Disseminated Candidiasis with Caspofungin and Itraconazole in a Patient with Progressive Acute Leukemia and Prolonged Neutropenia

International Journal of Hematology

Volumn 79, Issue 3, 2004, Pages 289-292

  Hübel, Kai ^a,b   Chemnitz, J ^a   Brochhagen, H G ^a   Cornely, O A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chronic disseminated candidiasis; Neutropenia; Progressive leukemia; Therapy

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CASPOFUNGIN; CEFTRIAXONE; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; GENTAMICIN; IDARUBICIN; INTERLEUKIN 2; ITRACONAZOLE; MEROPENEM; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANDIDA; CANDIDIASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; NEUTROPENIA;

EID: 2442616195     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0315     Document Type: Article

References (20)

1. Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer. 2001;92:1349-1353.
2. Sallah S, Semelka R, Kelekis N, Worawattanakul S, Sallah W. Diagnosis and monitoring response to treatment of hepatosplenic candidiasis in patients with acute leukemia using magnetic resonance imaging. Acta Haematol. 1998;100:77-81.
3. Derenski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36: 1445-1457.
4. Quintini G, Barbera V, Gambino R, Spadola V, Minardi V, Mariani G. Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunirubucin and fluconazole. Haematologica. 2001;86:E18.
5. Colovic M, Lazarevic V, Colovic R, et al. Hepatosplenic candidiasis after neutropenic phase of acute leukemia. Med Oncol. 1999;16: 139-142.
6. Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87:535-541.
7. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
8. Karthaus M, Huebner G, Elser C, Geissler RG, Heil G, Ganser A. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation. Ann Hematol. 1998;77: 41-45.
9. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am. 2000;14:721-739.
10. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246-254.
11. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.
12. Johnsons MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother. 2003;4:807-823.
13. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45 (suppl 3):56-60.
14. Diamond RD. Interactions of phagocytic cells with Candida and other opportunistic fungi. Arch Med Res. 1993;24:361-369.
15. Gaviria JM, van Burk J-AH, Dale DC, Root RK, Liles WC. Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis. 1999;179:1301-1304.
16. Rokusz L, Liptay L, Kadar K. Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination. Scand J Infect Dis. 2001;33:784-786.
17. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer. 1995;76:2357-2362.
18. Katayama K, Koizumi S, Yamagami M, et al. Successful peritransplant therapy in children with active hepatosplenic candidiasis. Int J Hematol. 1994;59:125-130.
19. Meloni G, Trisolini SM, Capria S, et al. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia. 2002;16:2016-2018.
20. Maraninchi D, Vey N, Viens P, et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma. 1998;31:343-349.